STOCK TITAN

Labcorp Holdings Inc - LH STOCK NEWS

Welcome to our dedicated page for Labcorp Holdings news (Ticker: LH), a resource for investors and traders seeking the latest updates and insights on Labcorp Holdings stock.

Overview of Labcorp Holdings Inc (LH)

Labcorp Holdings Inc is a comprehensive provider of clinical diagnostics and laboratory services, renowned for its decades of scientific expertise and innovation in medical testing. Operating in diverse segments including routine clinical tests, precision oncology, and genomic profiling, Labcorp offers a wide array of laboratory services essential for improved patient care and informed therapeutic decisions. Integrated testing solutions and advanced diagnostic capabilities are at the heart of its operations, underscoring its role as a central partner for physicians, hospitals, and biopharmaceutical companies.

Comprehensive Laboratory Services and Expertise

At its core, Labcorp specializes in high-quality, timely laboratory testing that covers a vast range of assays—from routine blood and urine screens to complex molecular and genetic tests. Its sophisticated laboratory network is equipped with state-of-the-art technologies that enable advanced clinical and anatomic pathology, esoteric testing, and genomic sequencing. This strategic application of scientific innovations ensures that the company consistently delivers accurate and actionable results, which are crucial for diagnostic precision and personalized healthcare.

Integrated Business Model and Operational Excellence

Labcorp generates revenue through a diversified business model that includes direct sales of clinical tests, integrated services for research and drug development, and strategic partnerships with healthcare providers and biopharma organizations. The company leverages its deep scientific expertise to offer high-volume diagnostic services through numerous patient-service centers and central laboratories worldwide. With decades of experience, Labcorp continuously adapts its processes to integrate advances in automation, data analytics, and digital health solutions, thereby streamlining operations and enhancing test reliability.

Precision Oncology and Genomic Profiling

A core area of Labcorp’s expertise is in precision oncology, where the company employs advanced genomic profiling techniques to support targeted cancer therapies. Its extensive portfolio of precision oncology assays, including liquid biopsy tests and tissue-based genomic profiling, enables healthcare providers to obtain critical insights into tumor biology. This capability not only supports personalized treatment strategies but is also instrumental for biopharmaceutical research and the development of innovative cancer therapies.

Serving a Broad Healthcare Ecosystem

Labcorp’s client base spans across physician offices, hospitals, managed care organizations, and pharmaceutical companies. Its services are fundamental to multiple aspects of healthcare delivery, from routine patient care to cutting-edge research initiatives. By offering an extensive range of diagnostic tests and integrated solutions, Labcorp plays a pivotal role in enabling evidence-based clinical decisions and supporting complex drug development processes.

Scientific Innovation and Industry Leadership

Labcorp is recognized for its rigorous commitment to quality and scientific precision, underscored by its continuous investment in research and technological advancements. The company’s expertise in areas such as esoteric testing, clinical genomics, and comprehensive disease profiling positions it as a trusted resource in the landscape of modern diagnostics. By harmonizing clinical insight with innovative laboratory methods, Labcorp ensures that its service offerings remain both cutting-edge and reliable.

Operational Reach and Global Impact

With a vast network of laboratories and patient-service centers, Labcorp ensures that a broad population is served with high-quality clinical diagnostics. Its operations extend globally, reflecting a commitment to improving health outcomes through widespread access to advanced testing services. The integration of technology and analytics supports its operational excellence, ensuring robust and consistent test results that are critical for clinical decision-making worldwide.

Commitment to Quality and Trust

Labcorp’s longstanding reputation is built on a foundation of expertise, stringent quality controls, and continuous innovation. The company adheres to rigorous clinical and regulatory standards, ensuring that every test meets the highest levels of accuracy and reliability. This trustworthiness, combined with its continuous advances in technology, reinforces Labcorp’s role as a key partner in the healthcare and life sciences sectors.

In summary, Labcorp Holdings Inc stands out through its broad portfolio of diagnostic solutions, deep scientific expertise, and a robust network that spans across critical sectors of healthcare. Its commitment to integrating advanced technology with clinical precision positions it as a highly reliable entity in the competitive landscape of laboratory services without resorting to speculative future claims.

Rhea-AI Summary
Xcell Biosciences Inc. deepens its partnership with Labcorp through new financing, beta access to clinical manufacturing instruments, and AACR data presentations. Labcorp increases its strategic investment in Xcellbio, joins Xcellbio's board of directors, and participates in the beta program for AVATAR™ instruments. Xcellbio and Labcorp will jointly present results at the AACR annual meeting, showcasing their cell and gene therapy collaboration.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.97%
Tags
none
-
Rhea-AI Summary
The Prelude Network expands its partnership with Labcorp to enhance genetic carrier screening services for patients, including genetic counseling and improved test result turnaround time. Labcorp's contract with insurance companies aims to improve financial access to genetic screening for the U.S. patient population, benefiting patients seeking fertility diagnostics and treatment options.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Labcorp (LH) to acquire select assets of BioReference Health from OPKO Health (OPK) to enhance laboratory services network and expand access to clinical laboratory services.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.87%
Tags
Rhea-AI Summary
Labcorp (LH) will release its financial results for Q1 2024 on April 25, 2024. A conference call and webcast will follow to discuss the results. The earnings press release will be available on Labcorp's Investor Relations website. Participants can register to receive dial-in numbers for the call. A replay will be accessible until April 11, 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.43%
Tags
-
Rhea-AI Summary
Labcorp (NYSE: LH) launches pTau217 test to aid in Alzheimer's disease diagnosis and monitoring, expanding its testing options. The company aims to improve patient care by providing innovative laboratory services in the field of Alzheimer's disease. The test complements Labcorp's existing biomarker testing portfolio, offering physicians and biopharmaceutical partners a valuable tool for clinical trials and research.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.76%
Tags
-
Rhea-AI Summary
Labcorp presents study results at SGO Annual Meeting on Women's Cancer emphasizing the value of biomarker testing in guiding targeted therapies for ovarian cancer patients. The studies highlight the importance of comprehensive genomic profiling in improving patient outcomes and access to effective treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Labcorp (LH) introduces Weight Loss Management portfolio to support individuals and physicians with convenient testing options. The offering includes educational resources and proven tests to guide weight loss decisions. GLP-1 medications and bariatric surgery are emphasized for effective weight management. The initiative targets the growing obesity epidemic in the U.S. and aims to provide essential health indicators for personalized treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.26%
Tags
none
-
Rhea-AI Summary
Pinnacle Fertility partners with Labcorp to enhance genetic testing services for patients. Labcorp brings over 50 years of experience in women's health and reproductive genetics, aiming to improve patient care and understanding of genetic factors affecting fertility.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.35%
Tags
partnership
-
Rhea-AI Summary
Labcorp (LH) provides 2024 guidance, reporting Q4 revenue of $3.03 billion, a 3.5% increase, and full-year revenue of $12.16 billion, a 2.5% increase. Adjusted EPS for Q4 was $3.30, full year $13.56, with a projected 2024 range of $14.30 to $15.40. Free cash flow for Q4 was $414.2 million, full year $748.7 million. Labcorp announced six new laboratory partnerships and innovative tests. The company closed a deal with Legacy Health and introduced a Fertility and Family Building Benefit. Labcorp's operating loss in Q4 was ($122.8) million, net losses were $(166.8) million, and diluted EPS was $(1.95). For the full year, net earnings were $380.4 million, diluted EPS $4.33. Operating income decreased to $725.6 million, adjusted EPS was $13.56, and free cash flow was $748.7 million. Revenue growth was driven by acquisitions, organic revenue, and foreign currency translation. Labcorp's 2024 guidance includes revenue growth of 4.7% to 6.5%, adjusted EPS of $14.30 to $15.40, and free cash flow of $1.00 billion to $1.15 billion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.62%
Tags
none
Rhea-AI Summary
Labcorp (NYSE: LH) has been named to FORTUNE® magazine's list of the World's Most Admired Companies™, recognizing the company's global leadership in innovative laboratory services. Labcorp was one of only five companies in the 'Health Care: Pharmacy and Other Services' industry to achieve Most Admired status, scoring high marks in long-term investment, global competitiveness, and social responsibility. The annual survey is conducted by FORTUNE and Korn Ferry, with top executives, directors, and financial analysts identifying companies with the strongest reputations across nine criteria.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.9%
Tags
none

FAQ

What is the current stock price of Labcorp Holdings (LH)?

The current stock price of Labcorp Holdings (LH) is $218.61 as of April 10, 2025.

What is the market cap of Labcorp Holdings (LH)?

The market cap of Labcorp Holdings (LH) is approximately 19.1B.

What core services does Labcorp Holdings Inc provide?

Labcorp offers a comprehensive range of laboratory services including routine clinical testing, advanced genomic profiling, and precision oncology diagnostics. Its service portfolio supports hospitals, physician offices, and biopharmaceutical companies.

How does Labcorp generate its revenue?

Revenue is generated through the direct provision of clinical diagnostic tests, integrated laboratory services for research and drug development, and strategic partnerships with healthcare providers. The diversified model ensures robust and consistent performance across multiple segments.

What distinguishes Labcorp in the marketplace?

Labcorp is distinguished by its decades of scientific expertise, sophisticated laboratory network, and commitment to quality and innovation. Its application of advanced technologies such as genomic sequencing and liquid biopsy further strengthens its competitive edge.

How does Labcorp support precision oncology?

Labcorp provides precision oncology services using comprehensive genomic profiling and liquid biopsy assays. These tests offer critical insights into tumor characteristics, aiding oncologists in developing personalized treatment strategies based on molecular data.

Who are the main customers of Labcorp?

Labcorp serves a broad spectrum of clients including hospitals, physician offices, managed care organizations, and biopharmaceutical companies. Its diagnostic services are essential for both routine patient care and advanced clinical research.

What role does innovation play at Labcorp?

Innovation is central to Labcorp's operations, as it continuously invests in state-of-the-art technologies and advanced testing methods. This focus on research and development ensures high accuracy, operational efficiency, and a wide reach of diagnostic capabilities.

How extensive is Labcorp’s network of laboratories?

Labcorp operates a sophisticated network of laboratories and patient-service centers, offering widespread access to its advanced diagnostic services. This extensive network enables efficient processing of clinical tests and supports its global operational footprint.

How does Labcorp integrate technology with healthcare services?

Labcorp integrates cutting-edge technology with clinical expertise by employing advanced digital health solutions, data analytics, and automated laboratory processes. This integration enhances test accuracy and operational efficiency, ensuring reliable results for clinical decision-making.
Labcorp Holdings Inc

NYSE:LH

LH Rankings

LH Stock Data

19.14B
83.32M
0.34%
96.06%
2.21%
Diagnostics & Research
Services-medical Laboratories
Link
United States
BURLINGTON